Figure 5.
Relationships evaluated in the framework for sunitinib in gastrointestinal stromal tumor. Solid lines indicate relationships included in the final models, and dashed lines indicate relationships investigated but not included in the final models. In contrast to the other adverse effects investigated, blood pressure was, however, better predicted by sunitinib daily area under the concentration–time curve (AUC) than soluble vascular endothelial growth factor receptor (sVEGFR)-3. Tumor size before treatment initiation (baseline) was a predictor in the final model of overall survival, whereas the relative change in sVEGFR-3 over time was a better predictor than other evaluated metrics of tumor size after start of treatment.2 The current analysis showed that absolute neutrophil count (ANC) and diastolic blood pressure (dBP) are, in combination, as good predictors of overall survival as is sVEGFR-3. HFS, hand–foot syndrome; sKIT, soluble stem cell factor receptor.